DOCSLIB.ORG

AIDS Pharmaceutical Assistance (APA) Formulary – December 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

AIDS Pharmaceutical Assistance (APA) Formulary – December 2020 In accordance with Health Resources and Services Administration (HRSA) Policy Clarification Notice 16-02 (dated Oct 2018), a Local Pharmaceutical Assistance Program (LPAP) is operated by a Ryan White Part A or B recipient or subrecipient as a supplemental means of providing medication assistance when an AIDS Drug Assistance Program (ADAP) has a restricted formulary, waiting list and/or restricted financial eligibility criteria. Florida ADAP has a restricted formulary. Therefore, the Florida Ryan White Part B Program has elected to have one APA formulary statewide and to manage a statewide medication formulary workgroup to advise on the APA formulary. LPAP funds are not to be used for Emergency Financial Assistance (EFA); the EFA category, however, may assist with medications not covered by the LPAP. Note: Combination products consisting of individual drugs that are listed on the APA are permitted, even if the combination product is not listed on the APA formulary. All dosage forms of drugs listed on the APA formulary can be purchased. GENERIC NAME THERAPEUTIC CLASSIFICATION PHARMACOLOGIC CLASSIFICATION acetaminophen with codeine Analgesic Opiate + prostaglandin inhibitor acetazolamide Antiglaucoma Carbonic anhydrase inhibitor, oral allopurinol Antigout Xanthine oxidase inhibitor alprazolam Central nervous system Benzodiazepine amiloride Cardiovascular Potassium-sparing diuretic amlodipine/atorvastatin Cardiovascular CCB/HMG-CoA reductase inhibitor combo amlodipine/benazepril Cardiovascular CCB/ACE inhibitor combo ammonium lactate Skin/Mucous membrane Humectant amphetamine/ dextroamphetamine Central nervous system Stimulant atomoxetine Central nervous system Norepinephrine reuptake inhibitor azelastine Respiratory Antihistamine baclofen Central nervous system Muscle relaxant beclomethasone Respiratory Corticosteroid, nasal beclomethasone Respiratory Corticosteroid, oral inhaled benztropine Central nervous system Anticholinergic bisacodyl Gastrointestinal Laxative, stimulant brimonidine Ophthalmic, antiglaucoma Alpha-2 agonist, ophthalmic brimonidine/timolol Ophthalmic, antiglaucoma Alpha-2 agonist + Beta-blocker budesonide Respiratory Corticosteroid, oral inhaled buprenorphine Substance abuse Opiate agonist/antagonist buprenorphine/naloxone Substance abuse Opiate agonist/antagonist buspirone Central nervous system Anxiolytic butalbital/acetaminophen/ caffeine Central nervous system Antimigraine calcium acetate Vitamin Vitamin calcium polycarbophil Gastrointestinal Laxative, bulk-forming Sodium-glucose co-transporter 2 inhibitor canagliflozin Antidiabetic (SGTL2) canagliflozin/metformin Antidiabetic SGTL2 + biguanide carbamazepine Central nervous system Anticonvulsant, mood stabilizer carbidopa/levodopa Neurological Dopamine agonist carvedilol Cardiovascular Beta-blocker celecoxib Analgesic Nonsteroidal anti-inflammatory drug cetirizine/pseudoephedrine Respiratory Antihistamine + decongestant chlorhexidine gluconate Skin/Mucous membrane Antibiotic, topical In accordance with Health Resources and Services Administration (HRSA) Policy Clarification Notice 16-02 (dated Oct 2018), a Local Pharmaceutical Assistance Program (LPAP) is operated by a Ryan White Part A or B recipient or subrecipient as a supplemental means of providing medication assistance when an AIDS Drug Assistance Program (ADAP) has a restricted formulary, waiting list and/or restricted financial eligibility criteria. Florida ADAP has a restricted formulary. Therefore, the Florida Ryan White Part B Program has elected to have one APA formulary statewide and to manage a statewide medication formulary workgroup to advise on the APA formulary. LPAP funds are not to be used for Emergency Financial Assistance (EFA); the EFA category, however, may assist with medications not covered by the LPAP. Note: Combination products consisting of individual drugs that are listed on the APA are permitted, even if the combination product is not listed on the APA formulary. All dosage forms of drugs listed on the APA formulary can be purchased. GENERIC NAME THERAPEUTIC CLASSIFICATION PHARMACOLOGIC CLASSIFICATION chlorthalidone Cardiovascular Thiazide diuretic ciprofloxacin Anti-infective, antibiotic Quinolone clidinium/chlordiazepoxide Gastrointestinal Anticholinergic + anxiolytic clindamycin/benzoyl peroxide Skin/Mucous membrane Antibiotic, topical clobetasol Skin/Mucous membrane Corticosteroid, topical clonazepam Central nervous system Benzodiazepine clonidine Cardiovascular Alpha-2 agonist clopidogrel Cardiovascular Platelet inhibitor clotrimazole/betamethasone Skin/Mucous membrane Antifungal + corticosteroid colchicine Antigout Anti-inflammatory, gout cyproheptadine Gastrointestinal Appetite stimulant dabigatran Blood formation and coagulation Anticoagulant desvenlafaxine Central nervous system Serotonin-norepinephrine reuptake inhibitor diclofenac Analgesic Nonsteroidal anti-inflammatory drug dicyclomine Gastrointestinal Antispasmodic disulfiram Substance abuse Alcohol deterrent docusate Gastrointestinal Laxative, stool softener donepezil Central nervous system Cholinesterase inhibitor dorzolamide Ophthalmic, antiglaucoma Carbonic anhydrase inhibitor dorzolamide/timolol Ophthalmic, antiglaucoma Carbonic anhydrase inhibitor + beta blocker doxycycline Anti-infective, antibiotic Tetracycline dry mouth moisturizing spray Skin/Mucous membrane Mucosal lubricant enalapril/hydrochlorothiazide Cardiovascular ACE inhibitor + thiazide epinephrine Cardiovascular Alpha and Beta agonist, non-selective esomeprazole Gastrointestinal Proton pump inhibitor eszopiclone Central nervous system Sedative-Hypnotic ethinyl estradiol/desogestrel Hormonal, contraceptive Estrogen/progestin combination ethinyl estradiol/drospirenone Hormonal, contraceptive Estrogen/progestin combination ethinyl estradiol/etonogestrel Hormonal, contraceptive Estrogen/progestin combination ethinyl estradiol/levonorgestrel Hormonal, contraceptive Estrogen/progestin combination ethinyl estradiol/norethindrone Hormonal, contraceptive Estrogen/progestin combination ethinyl estradiol/norethindrone/FE Hormonal, contraceptive Estrogen/progestin combination ethinyl estradiol/norgestimate Hormonal, contraceptive Estrogen/progestin combination ethinyl estradiol/norgestrel Hormonal, contraceptive Estrogen/progestin combination In accordance with Health Resources and Services Administration (HRSA) Policy Clarification Notice 16-02 (dated Oct 2018), a Local Pharmaceutical Assistance Program (LPAP) is operated by a Ryan White Part A or B recipient or subrecipient as a supplemental means of providing medication assistance when an AIDS Drug Assistance Program (ADAP) has a restricted formulary, waiting list and/or restricted financial eligibility criteria. Florida ADAP has a restricted formulary. Therefore, the Florida Ryan White Part B Program has elected to have one APA formulary statewide and to manage a statewide medication formulary workgroup to advise on the APA formulary. LPAP funds are not to be used for Emergency Financial Assistance (EFA); the EFA category, however, may assist with medications not covered by the LPAP. Note: Combination products consisting of individual drugs that are listed on the APA are permitted, even if the combination product is not listed on the APA formulary. All dosage forms of drugs listed on the APA formulary can be purchased. GENERIC NAME THERAPEUTIC CLASSIFICATION PHARMACOLOGIC CLASSIFICATION famciclovir Anti-infective, antiviral Antiherpetic agent fentanyl Analgesic Opiate fexofenadine Respiratory Antihistamine flecainide Cardiovascular Antiarrhythmic fludrocortisone Hormonal Corticosteroid fluocinolone Skin/Mucous membrane Corticosteroid, topical fluocinonide Skin/Mucous membrane Corticosteroid, topical fluorouracil Skin/Mucous membrane Antineoplastic fluticasone Respiratory Corticosteroid, nasal fluticasone Respiratory Corticosteroid, oral inhaled fluticasone/salmeterol Respiratory Corticosteroid + LABA, oral inhaled fluticasone/vilanterol Respiratory Corticosteroid + LABA, oral inhaled glipizide/metformin Antidiabetic Sulfonylurea + biguanide hydralazine Cardiovascular Antiangina hydrocodone/acetaminophen Analgesic Opiate + prostaglandin inhibitor hydrocortisone Skin/Mucous membrane Corticosteroid, topical hydrocortisone/pramoxine Skin/Mucous membrane Corticosteroid, topical hydroxyzine Respiratory Antihistamine hydroxyzine Central nervous system Anxiolytic isosorbide dinitrate Cardiovascular Antiangina, vasodilator isosorbide mononitrate Cardiovascular Antiangina, vasodilator labetalol Cardiovascular Beta-blocker lacosamide Central nervous system Anticonvulsant lactobacillus acidophilus Gastrointestinal Probiotic latanoprost Ophthalmic, antiglaucoma Prostaglandin, ophthalmic lidocaine Skin/Mucous membrane Anesthetic, topical Glucagon-like peptide-1 (GLP-1) receptor liraglutide Antidiabetic agonist loratadine/pseudoephedrine Respiratory Antihistamine + decongestant lorazepam Central nervous system Benzodiazepine losartan/hydrochlorothiazide Cardiovascular ARB + thiazide lurasidone Central nervous system Antipsychotic, antimanic magnesium oxide Nutritional supplement Nutritional supplement melatonin Central nervous system Hormonal, anti-insomnia meloxicam Analgesic Nonsteroidal anti-inflammatory drug In accordance with Health Resources and Services Administration (HRSA) Policy Clarification Notice 16-02 (dated Oct 2018), a Local Pharmaceutical Assistance Program (LPAP) is operated by a Ryan White Part A or B recipient or subrecipient
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al

    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate

    Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate

    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
  • Etats Rapides

    Etats Rapides

    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
  • Fluocinolone Acetonide Promotes the Proliferation and Mineralization Of

    Fluocinolone Acetonide Promotes the Proliferation and Mineralization Of

    Basic Research—Biology Fluocinolone Acetonide Promotes the Proliferation and Mineralization of Dental Pulp Cells Zhongning Liu, DDS, MS,* Ting Jiang, DDS, PhD,* Yixiang Wang, DDS, MS,† and Xinzhi Wang, DDS, PhD* Abstract Introduction: The aim of this study was to investigate Key Words the role of the steroid fluocinolone acetonide on the Dental pulp cells, fluocinolone acetonide, mineralization, proliferation proliferation and mineralization of human dental pulp cells (DPCs). The potential effect of fluocinolone aceto- he recovery of injured dental pulp is still one of the unresolved clinical problems. nide on reparative dentin formation and the recovery TWhen unexpected pulp exploration occurs, the survival of vital pulp will be more of injured dental pulp were evaluated. Methods: The difficult. Because healthy and vital pulp can promise a better prognosis of the injured proliferative effect of fluocinolone acetonide on DPCs tooth, preserving the vitality of pulp tissue is of key importance for long-time tooth pres- was analyzed by cholecystokinin octapeptide assay ervation (1). The ideal dental pulp capping agent should not only induce the formation and flow cytometry. The mineralized effect of fluocino- of reparative dentin but also inhibit inflammatory processes. The widely used capping lone acetonide was investigated by the detection of agents (ie, calcium hydroxide and mineral trioxide aggregate) are mainly focused on mineralization-related biomarkers including alkaline the closure of the exposed pulp; however, they are short of the anti-inflammation effect. phosphatase (ALP), bone sialoprotein, and osteocalcin So far, there is no ideal dental pulp capping material for the repair of slightly inflam- by using ALP histochemical staining, ALP activity, immu- matory pulp cases.
  • Aspects of the Bioavailability of Topical Corticosteroid

    Aspects of the Bioavailability of Topical Corticosteroid

    - - ASPECTS OF THE BIOAVAILABILITY OF TOPICAL CORTICOSTEROID FORMULATIONS. A Thesis Submitted to RHOD ES UNIVERSITY in Partial Fulfilment of the Requirements for the Degree of MASTER OF SCIENCE by ASHLEY DENIS MAGNUS B.Pharm.(Rhodes) School of Pharmaceutical Sciences, Rhodes University, Grahamstown, South Africa. 6140 November 1978. - i - CONTENTS ABSTRACT iii ACKNOWLEDGEMENTS iv PREPARATIONS v STANDARDS vi INSTRUMENTA TION vii STRUCTURES viii 1. INTRODUCTION 1 1.1 BIOASSAYS USED TO ASSESS TOPICAL STEROID ACTIVITY 1 1. 2 TEE HUMAN VASOCONSTRICTOR ASSAY AS A MEASURE OF TOPICAL STEROID ACTIVITY 5 1 .2.1 Alcoholic Vasoconstrictor Studies 5 1.2.2 Studies of Vasoconstriction in Other Solvents 9 1.2.3 Studied of Vasoconstri ction in Formulated Products 10 1. 3 THE MECHANISM OF BLANCHING 1 6 1.4 THE SKIN AS A CORTICOSTEROID RESERVOIR 18 1. 5 TEE CORRELATION OF VASOCONSTRICTOR ACTIVITY WITE CLINICAL EFFICACY 19 1. 6 THE EFFECT OF EXTEMPORANEOUS DILUTION OF TOPICAL CORTICO- STEROID FORMULATIONS 20 1.6.1 Pharmaceutical Considerations 21 1.6.2 Bacteriological Consider ations 22 1.6.3 Biopharmaceutical Considerations 23 2. METHODS 24 2.1 TEE BLANCHING ASSAY 24 2.1 .1 Volunteers 24 2.1 . 2 Mode of Application 24 2 .1.3 Reading of Results 26 2.2 STATISTICAL EVALUATION 27 2 . 3 CALCULATION OF PERCENT TOTAL POSSIBLE SCORE (% TPS) 28 2.4 DETERMINATION OF AREA UNDER THE BLANCHING PROFILE 28 3. DISCUSSION 31 3 .1 TEE ASSESSMENT OF VARIABLES AFFECTING TEE BLANCHING ABILITY OF FORMULATED PRODUCTS 31 - ii - CONTENTS (continued)/ 3.1. 1 The Effect of the Amount of Formulated Product Applied to the Test Site 32 3.
  • Aqueous Clear Solutions of Fluocinolone Acetonide for Treatment

    Aqueous Clear Solutions of Fluocinolone Acetonide for Treatment

    (19) & (11) EP 2 366 408 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 47/10 (2006.01) A61K 47/12 (2006.01) 18.07.2012 Bulletin 2012/29 A61K 47/14 (2006.01) A61K 47/32 (2006.01) A61K 47/38 (2006.01) A61K 9/00 (2006.01) (2006.01) (21) Application number: 10155005.1 A61K 31/58 (22) Date of filing: 01.03.2010 (54) Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation Wässrige klare Lösungen aus Fluocinolon-Acetonid zur Behandlung von Ohrentzündungen Solutions claires aqueuses d’acétonide de fluocinolone pour le traitement de l’inflammation otique (84) Designated Contracting States: • Izquierdo Torres, Francisca AT BE BG CH CY CZ DE DK EE ES FI FR GB GR E-08950 HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL Esplugues de LLobregat - Barcelona (ES) PT RO SE SI SK SM TR (74) Representative: ABG Patentes, S.L. (43) Date of publication of application: Avenida de Burgos, 16D 21.09.2011 Bulletin 2011/38 Edificio Euromor 28036 Madrid (ES) (73) Proprietor: Laboratorios SALVAT, S.A. 08950 Esplugues de Llobregat, Barcelona (ES) (56) References cited: EP-A1- 0 995 435 DE-A1- 2 515 594 (72) Inventors: GB-A- 1 013 180 GB-A- 1 133 800 • Ruiz i Pol, Jaume GB-A- 1 411 432 US-A1- 2009 325 938 E-08950, US-A1- 2010 036 000 Esplugues de LLobregat-Barcelona (ES) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
  • 2020 NY44 Formulary

    2020 NY44 Formulary

    2020 NY44/ Pharmacy Benefit Dimensions Drug Formulary This Drug Formulary represents the list of drugs and their appropriate copayment tiers for members of the NY44 Health Benefits Plan Trust. Note: If you are reading a printed version of this drug formulary, content may have been updated since it was last printed. For the most up-to-date information, please visit www.pbdrx.com. Drug Formulary Introduction Generic drugs appear in lower case. Brand name drugs are capitalized. This formulary lists all covered Tier 1 and Tier 2 drugs, but only lists representative products in Tier 3. Formulary/preferred generic drugs and select Over the Counter (OTC) and select Brand Name drugs listed on the Formulary are assigned to copay Tier 1. The formulary follows a “Mandatory Generic” policy which means that in most instances, once a generic product is available for which there are no bioequivalence concerns, the branded product is assigned to Copay Tier 3, and the generic product is assigned to Copay Tier 1. Certain non- preferred generic drugs may also be covered in the 3rd tier when efficacy, safety or cost factors suggest that better alternatives exist on the formulary. Not all tier 3 non-preferred drugs are listed in the formulary. For members with a 3 tier plan, most drugs not listed may be obtained, but the member will be responsible for their third tier copayment. Pharmacy Benefit Dimensions reserves the right to modify the copay tier of a particular drug as necessary. For example, the copay tier of a brand drug will be raised from Tier 2 to Tier 3 when a generic drug becomes available (the generic drug will be placed in copay Tier 1).
  • Contact Dermatitis to Medications and Skin Products

    Contact Dermatitis to Medications and Skin Products

    Clinical Reviews in Allergy & Immunology (2019) 56:41–59 https://doi.org/10.1007/s12016-018-8705-0 Contact Dermatitis to Medications and Skin Products Henry L. Nguyen1 & James A. Yiannias2 Published online: 25 August 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Consumer products and topical medications today contain many allergens that can cause a reaction on the skin known as allergic contact dermatitis. This review looks at various allergens in these products and reports current allergic contact dermatitis incidence and trends in North America, Europe, and Asia. First, medication contact allergy to corticosteroids will be discussed along with its five structural classes (A, B, C, D1, D2) and their steroid test compounds (tixocortol-21-pivalate, triamcinolone acetonide, budesonide, clobetasol-17-propionate, hydrocortisone-17-butyrate). Cross-reactivities between the steroid classes will also be examined. Next, estrogen and testosterone transdermal therapeutic systems, local anesthetic (benzocaine, lidocaine, pramoxine, dyclonine) antihistamines (piperazine, ethanolamine, propylamine, phenothiazine, piperidine, and pyrrolidine), top- ical antibiotics (neomycin, spectinomycin, bacitracin, mupirocin), and sunscreen are evaluated for their potential to cause contact dermatitis and cross-reactivities. Finally, we examine the ingredients in the excipients of these products, such as the formaldehyde releasers (quaternium-15, 2-bromo-2-nitropropane-1,3 diol, diazolidinyl urea, imidazolidinyl urea, DMDM hydantoin), the non- formaldehyde releasers (isothiazolinones, parabens, methyldibromo glutaronitrile, iodopropynyl butylcarbamate, and thimero- sal), fragrance mixes, and Myroxylon pereirae (Balsam of Peru) for contact allergy incidence and prevalence. Furthermore, strategies, recommendations, and two online tools (SkinSAFE and the Contact Allergen Management Program) on how to avoid these allergens in commercial skin care products will be discussed at the end.
  • Public Assessment Report Mutual Recognition Procedure ILUVIEN

    Public Assessment Report Mutual Recognition Procedure ILUVIEN

    Public Assessment Report Mutual Recognition Procedure ILUVIEN® 190 micrograms Intravitreal Implant in Applicator (Fluocinolone acetonide) UK/H/3011/001/E01 UK licence no: PL 41472/0001 Alimera Sciences Limited PAR ILUVIEN 190 micrograms intravitreal implant in applicator UK/H/3011/001/E01 LAY SUMMARY ILUVIEN® 190 micrograms intravitreal implant in applicator (fluocinolone acetonide) This is a summary of the Public Assessment Report (PAR) for ILUVIEN® 190 micrograms intravitreal implant in applicator (PL 41472/0001; UK/H/3011/001/E01). It explains how ILUVIEN® 190 micrograms intravitreal implant in applicator was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use ILUVIEN® 190 micrograms intravitreal implant in applicator. The product will be referred to as ILUVIEN throughout the remainder of this lay summary. For practical information about using ILUVIEN, patients should read the package leaflet or contact their doctor or pharmacist. What is ILUVIEN and what is it used for? ILUVIEN is used to treat vision loss associated with diabetic macular oedema when other available treatments have failed to help. Diabetic macular oedema is a condition that affects some people with diabetes, and causes damage to the light-sensitive layer at the back of the eye responsible for central vision, the macula. The active ingredient, fluocinolone acetonide, helps to reduce the inflammation and the swelling that builds up in the macula in this condition. ILUVIEN can therefore help to improve the damaged vision or stop it from getting worse. How is ILUVIEN used? ILUVIEN is given as a single injection into the eye by a doctor.
  • Wo 2008/127291 A2

    Wo 2008/127291 A2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.